A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

Launched by AIMEI VACIN BIOPHARM (ZHEJIANG) CO., LTD. · Mar 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new vaccine called the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, which aims to protect against meningococcal meningitis, a serious infection that can affect the brain and spinal cord. The trial will include 1,200 participants aged between 3 months and 15 years. They will be divided into groups based on age, and participants will receive either the experimental vaccine or a control vaccine to see how well it works and if it is safe.

To join the trial, children must meet certain criteria, such as being within the specified age range and having not received any meningococcal vaccines previously, except in specific cases. Parents or guardians must also agree to their child’s participation by signing a consent form. During the study, younger children will receive multiple doses of the vaccine at specific intervals, while older children will receive just one dose. Participants will be monitored for any side effects, and the study is currently not recruiting participants yet. This trial is important as it could lead to better protection against a potentially life-threatening disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * 3\~5 months old:
• • 1. 3\~5 months old;
• • 2. The subject's legal guardian voluntarily agrees to his or her child's participation in this trial and signs an informed consent form;
• • 3. The subject and/or the subject's legal guardian can comply with the relevant requirements of the clinical trial protocol;
• • 4. Have not vaccinated by any meningococcal vaccine in the past.
• * 6\~23 months old:
• • 1. 6\~23 months old;
• • 2. The subject's legal guardian voluntarily agrees to his or her child's participation in this trial and signs an informed consent form;
• • 3. The subject and/or the subject's legal guardian can comply with the relevant requirements of the clinical trial protocol;
• • 4. Have not vaccinated by any other meningococcal vaccines except meningococcal group A polysaccharide vaccine in the past. If have 1 dose vaccinated of meningococcal group A polysaccharide vaccine, it will be 3 months or more separated from the previous dose of meningococcal group A polysaccharide vaccine. If two doses of meningococcal group A polysaccharide vaccine have been vaccinated, the interval between the last dose of meningococcal group A polysaccharide vaccine should be more than 6 months or more.
• * 2\~15 years old:
• • 1. 2\~15 years old;
• • 2. The subject's legal guardian voluntarily agrees to his or her child's participation in this trial and signs an informed consent form (subjects aged 8-15 years old are also required to sign an informed consent form);
• • 3. The subject and/or the subject's legal guardian can comply with the relevant requirements of the clinical trial protocol; Subjects aged 2 to 6 years old have not previously been vaccinated with any meningococcal vaccine other than meningococcal polysaccharide vaccine, and the interval between the previous dose of meningococcal polysaccharide vaccine and vaccination should be more than 12 months or more; 7\~15 years old participants have not received any meningococcal vaccine in the past 3 years.
• Exclusion Criteria:
• • 1. The temperature before vaccination on the day of vaccination is \>37.0℃;
• • 2. Have a history of invasive disease caused by meningococci confirmed by culture;
• • 3. Have a history of severe allergic reactions that require medical intervention (such as oral and throat swelling, dyspnea, hypotension or shock caused by allergies); have a history of allergies to vaccines or vaccine components (especially those allergic to diphtheria toxoid), and have concerns about vaccination History of other serious adverse reactions;
• • 4. Those with a clearly diagnosed history of thrombocytopenia or other coagulation disorders, which may cause contraindications for intramuscular injection;
• • 5. Suffer from acute disease or acute attack of chronic disease within 3 days before vaccination;
• • 6. Have a history of epilepsy, progressive neurological disease, Guillain-Barré syndrome, convulsions (except simple febrile convulsions) and mental illness;
• • 7. Known or suspected immunological dysfunction, including immunosuppressant treatment (radiation therapy, chemotherapy, corticosteroids, antimetabolites, cytotoxic drugs), human immunodeficiency virus (HIV) infection, etc.;
• • 8. Known severe congenital malformations; suffering from developmental disabilities or clinically diagnosed serious chronic diseases (such as Down syndrome, diabetes, sickle cell anemia or neurological diseases);
• • 9. Known or suspected to have serious diseases that are judged by the researcher to affect vaccination, including respiratory diseases, digestive system diseases, endocrine system diseases, immune system diseases, cardiovascular diseases, liver and kidney diseases, malignant tumors, skin diseases, etc. ;
• • 10. Long-term use (continuous use for ≥14 days) of immunosuppressants or other immunomodulatory drugs (such as corticosteroids: prednisone or similar drugs) within 6 months before vaccination with the experimental vaccine, but local use (such as ointments, eye drops, inhalants, or nasal sprays), topical administration should not exceed the dosage recommended in the label;
• • 11. Have received blood products including gamma globulin or immune globulin treatment within 3 months before vaccination (\<3 months);
• • 12. Asplenia or functional asplenia, asplenia or splenectomy caused by any condition;
• • 13. Have been vaccinated with live attenuated vaccines within 14 days (including 14 days) before vaccination, and have been vaccinated with other subunits, inactivated vaccines or recombinant protein vaccines other than live attenuated vaccines within 7 days (including 7 days);
• • 14. Currently participating in or planning to participate in other drug clinical trials during the entire trial period after receiving the experimental vaccine;
• • 15. Any situation that the researcher believes may affect the evaluation of the trial.